Key Insights

Highlights

Treatment Research

9 treatments under study, led by Cyclophosphamide

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 1/2 (1)
Phase 3 (1)

Trial Status

Active Not Recruiting2

Clinical Trials (2)

Showing 2 of 2 trials
NCT03960840Phase 1/2Active Not Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT06356129Phase 3Active Not Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Showing all 2 trials

Research Network

Common Treatments

  • Cyclophosphamide1
  • Ibrutinib1
  • Vincristine1
  • Golcadomide1
  • Prednisone1

Active Sponsors

  • Celgene Corp.1
  • Novartis Pharma AG1
  • Novartis Pharmaceuticals1
  • Celgene1

Related Conditions

  • Large Bcell Lymphoma2
  • Chronic Lymphocytic Leukemiasmall Lymphocytic Lymphoma1
  • Acute Lymphoblastic Leukemia1
  • Diffuse Large Bcell Lymphoma1
  • Chronic Lymphocytic Leukemia1

Activity Timeline